

FSD Pharma

09:30 04 Feb 2020

FSD Pharma amends deal with Solarvest BioEnergy to accelerate progress of CBD project

FSD Pharma Inc (CSE:HUGE) (NASDAQ:HUGE), the specialty biotech, revealed it had amended its deal with Solarvest Bioenergy Inc designed to accelerate progress on the latter's CBD research project.

As reported in May last year, Solarvest (CVE:SVS), based in Vancouver, British Columbia, holds a platform capable of producing health products from algae.

READ: FSD Pharma strikes deal with Solarvest BioEnergy to develop pharmaceutical-grade cannabinoids from algae

The project, run by Solarvest, is determining if its algal expression system can create pharmaceutical-grade cannabinoids and has made progress towards this goal, said FSD.

Since this is a cost-intensive project, and, to enable Solarvest to accelerate the pace of the research, FSD Pharma has issued a further 225,371 of its shares to Solarvest, it also revealed in Tuesday's statement.

In addition, Solarvest has appointed the current president of FSD Pharma's BioSciences division - Dr. Edward J. Brennan, Jr - to its board of directors.

"The parties have also mutually agreed that Solarvest would benefit from the additional oversight of Dr. Brennan, who brings with him over 25 years of experience in leadership roles at major pharmaceutical companies and clinical research organizations and has a proven track record in drug development," said Ontario-headquartered FSD.

Significant potential benefits

There could be significant benefits to FSD Pharma.

If the CBD research project is successful, Solarvest is required to grant FSD an exclusive, worldwide license to develop and commercialize prescription drugs that can treat diseases affecting the central nervous system.

Solarvest will additionally provide FSD Pharma with a royalty fee on the sale or licensing of certain products derived from the project.

Solarvest owns numerous key patents. Its organic Omega-3 patent application has been filed and is pending in Europe, UK, USA, Canada, Japan, India, China, S. Korea, Hong Kong and Australia.

Being algae-based, the products are suitable for vegetarian and vegan diets.

Shares in FSD Pharma nudged up 2.66% to C\$8.11 in early Toronto deals.

---Updates for share price---

Price: 2.33

Market Cap: \$44.65 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: HUGE

Listing: CSE

52 week	High	Low
	15.1	2.31

Sector: Pharma & Biotech

Website: fsdpharma.com

Company Synopsis:

FSD Pharma Inc. is a publicly-traded holding company, since May 2018. FSD Pharma BioSciences, Inc. , a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, ultramicronized-palmitoylethanolamide ("FSD201"), by down-regulating the cytokines to effectuate an anti-inflammatory response.

action@proactiveinvestors.com

Contact the author at giles@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).